Literature DB >> 32266771

Successful treatment of a refractory pyoderma gangrenosum with risankizumab.

Birte Burgdorf1, Swantje Schlott1, Ivaylo H Ivanov1, Joachim Dissemond2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32266771     DOI： 10.1111/iwj.13359

Source DB:  PubMed          Journal:  Int Wound J        ISSN： 1742-4801            Impact factor:   3.315


× No keyword cloud information.
  5 in total

1.  Resource-Limited Management of Presumptive Pyoderma Gangrenosum in an Unsheltered Patient.

Authors:  Taha F Rasul; Megan Mathew; Jackson D Anderson; Daniel R Bergholz; Armen Henderson
Journal:  Cureus       Date:  2022-01-26

2.  Modified dose of guselkumab for treatment of pyoderma gangrenosum.

Authors:  Ashley M Reese; Katherine Erickson; Katherine B Reed; Alex G Ortega-Loayza
Journal:  JAAD Case Rep       Date:  2022-01-06

3.  Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Final analysis of a 52-week phase 3 open-label study.

Authors:  Kenshi Yamasaki; Keiichi Yamanaka; Yiwei Zhao; Shunsuke Iwano; Keiko Takei; Koji Suzuki; Toshiyuki Yamamoto
Journal:  J Dermatol       Date:  2022-03-03       Impact factor: 3.468

4.  Recalcitrant Ulcerative Pyoderma Gangrenosum of the Leg Responsive to Tildrakizumab: A Case Report.

Authors:  Liang Joo Leow; Nicolas Zubrzycki
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-08-23

Review 5.  Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments.

Authors:  Carlo Alberto Maronese; Matthew A Pimentel; May M Li; Alex G Ortega-Loayza; Angelo Valerio Marzano; Giovanni Genovese
Journal:  Am J Clin Dermatol       Date:  2022-05-24       Impact factor: 6.233
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.